Amarantus Provides Comprehensive Corporate Update •
The original release is unavailable here.
Amarantus Bioscience Holdings, Inc. on 6ix
Earlier from Amarantus Bioscience
- Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
- Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.
- Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
- Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld
- Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Later from Amarantus Bioscience
- Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
- Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
- Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF
- Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
- Amarantus Subsidiary MANF Therapeutics Announces Retinal Patent Issuances in Europe Covering MANF & CDNF and Positive Data for MANF in Glaucoma
Follow Amarantus Bioscience into a list and get an email when it puts out news.
Follow Amarantus Bioscience